{'52WeekChange': 0.11697447,
 'SandP52WeekChange': 0.0644362,
 'address1': '88 Sidney Street',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 56.93,
 'askSize': 1000,
 'averageDailyVolume10Day': 396587,
 'averageVolume': 688428,
 'averageVolume10days': 396587,
 'beta': 2.133333,
 'beta3Year': None,
 'bid': 50.79,
 'bidSize': 1100,
 'bookValue': 9.09,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 51.59,
 'dayLow': 49.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -8.48,
 'enterpriseToRevenue': 17.635,
 'enterpriseValue': 3082312448,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 51.838856,
 'fiftyTwoWeekHigh': 56.75,
 'fiftyTwoWeekLow': 27.77,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 61032546,
 'forwardEps': -4.73,
 'forwardPE': -10.739958,
 'fromCurrency': None,
 'fullTimeEmployees': 536,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.113690004,
 'heldPercentInstitutions': 1.021,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/agios.com',
 'longBusinessSummary': 'Agios Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, engages in the discovery and development of '
                        'medicines in the field of cellular metabolism and '
                        'adjacent areas of hematologic malignancies, solid '
                        'tumors, and rare genetic diseases. The company offers '
                        'TIBSOVO (ivosidenib), an oral targeted inhibitor for '
                        'treating adult patients with relapsed or refractory '
                        'acute myeloid leukemia (R/R AML), as well as to treat '
                        'patients with newly diagnosed AML; and IDHIFA, an '
                        'oral targeted inhibitor for patients with R/R AML and '
                        'an isocitrate dehydrogenase 2 mutation. It is also '
                        'developing TIBSOVO, which has completed Phase II '
                        'clinical trials to treat IC eligible frontline AML; '
                        'that is in Phase III clinical trials for treating IC '
                        'ineligible frontline AML; and that is in Phase III '
                        'clinical trials for the treatment of '
                        'cholangiocarcinoma, as well as in early stage '
                        'clinical development to treat glioma and solid '
                        'tumors. In addition, the company is developing '
                        'IDHIFA, which has completed Phase II clinical study '
                        'for treating IC eligible frontline AML; and that is '
                        'in Phase I/II clinical trials for the treatment of IC '
                        'ineligible frontline AML. Further, it is developing '
                        'mitapivat, which is in Phase III clinical trials to '
                        'treat pyruvate kinase deficiency, as well as in Phase '
                        'II clinical study for treating thalassemia; '
                        'vorasidenib (AG-881) that is in Phase I clinical '
                        'trials for the treatment of solid tumors, including '
                        'glioma; AG-270, which is in Phase I dose-escalation '
                        'trial to treat methylthioadenosine phosphorylase '
                        'deleted cancers; and AG-636 that is in pre-clinical '
                        'stage for treating hematologic malignancies. Agios '
                        'Pharmaceuticals, Inc. was incorporated in 2007 and is '
                        'based in Cambridge, Massachusetts.',
 'longName': 'Agios Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 3499581440,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_46539787',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -358649984,
 'nextFiscalYearEnd': 1640908800,
 'open': 51.59,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.27,
 'phone': '617 649 8600',
 'previousClose': 52.18,
 'priceHint': 2,
 'priceToBook': 5.5885587,
 'priceToSalesTrailing12Months': 20.022434,
 'profitMargins': -2.05197,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 51.59,
 'regularMarketDayLow': 49.9,
 'regularMarketOpen': 51.59,
 'regularMarketPreviousClose': 52.18,
 'regularMarketPrice': 51.59,
 'regularMarketVolume': 536884,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 68889400,
 'sharesPercentSharesOut': 0.1083,
 'sharesShort': 7458952,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7637854,
 'shortName': 'Agios Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.168,
 'shortRatio': 11.16,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'AGIO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -5.735,
 'twoHundredDayAverage': 47.088272,
 'volume': 536884,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.agios.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}